Comparable stake leader
ARMISTICE CAPITAL, LLC
SEC ownership of Aridis Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001614067.
Disclosed value leader
Vu L. Truong
Comparable rows
1/10
Latest evidence
30 Jun 2026
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ARMISTICE CAPITAL, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
1 of 10
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ARMISTICE CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001614067
- Issuer location
- Los Gatos, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Aridis Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
Vu L. Truong
Comparable rows
1/10
Latest evidence
30 Jun 2026
13D/G
3/4/5
Lead comparable stake: 11%
9 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-8 of 10 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 11%.
1 of 10 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 1
ARMISTICE CAPITAL, LLC
11%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 10 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
11%
|
—
5,096,251 shares
|
$0 | 30 Jun 2026 |
| Cystic Fibrosis Foundation |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
5,168,732 shares
|
— | 08 Dec 2022 |
| Vu L. Truong |
3/4/5
CEO, Director
|
—
mixed-class rows
|
$96,505
2,196,389 shares
mixed-class rows
|
— | 24 Jun 2024 |
| Eric Patzer |
3/4/5
Director
|
—
mixed-class rows
|
$61,922
1,046,462 shares
mixed-class rows
|
— | 24 Jun 2024 |
| Hasan Jafri |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
—
382,495 shares
|
— | 27 Jun 2024 |
| John F. Hamilton |
3/4/5
Director
|
—
class O/S missing
|
—
269,040 shares
|
— | 27 Jun 2024 |
| Richards Windham Bannister |
3/4/5
Director
|
—
class O/S missing
|
—
261,000 shares
|
— | 27 Jun 2024 |
| Fred Kurland |
3/4/5
CFO
|
—
mixed-class rows
|
—
92,575 shares
mixed-class rows
|
— | 04 May 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 20 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-9 of 9 reporting-owner rows connected to Aridis Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
9
Largest Forms 3/4/5 holder
Vu L. Truong
Net 12M change
$0
Latest report
27 Jun 2024
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Vu L. Truong | CEO, Director | $96,505 | Filing P/S | 24 Jun 2024 | ||
| Eric Patzer | Director | $61,922 | Filing P/S | 24 Jun 2024 | ||
| Fred Kurland | Cfo | Mixed | 04 May 2023 | |||
| Richards Windham Bannister | Director | Mixed | 27 Jun 2024 | |||
| Robert R. Ruffolo | Director | Mixed | 05 Dec 2022 | |||
| Craig S. Gibbs | Director | Mixed | 05 Dec 2022 | |||
| Cystic Fibrosis Foundation | 10%+ Owner | Mixed | 08 Dec 2022 | |||
| Hasan Jafri | Chief Medical Officer | Mixed | 27 Jun 2024 | |||
| John F. Hamilton | Director | Mixed | 27 Jun 2024 |
Recent insider transactions for Aridis Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.